Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And OthersInvestors Business Daily • 11/14/22
Prothena Reports Third Quarter 2022 Financial Results and Business HighlightsBusiness Wire • 11/03/22
Prothena to Present Data on Survival Benefit Observed in Completed Phase 3 Study of Drug Candidate Birtamimab in Patients with Mayo Stage IV AL Amyloidosis at the ASH 2022 MeetingBusiness Wire • 11/03/22
Prothena (PRTA) Down 16.9% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 09/07/22
Prothena Announces Appointment of Biotechnology Industry Leader Helen S. Kim to its Board of DirectorsGlobeNewsWire • 09/01/22
Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer's DiseaseGlobeNewsWire • 04/26/22
Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer's DiseaseGlobeNewsWire • 03/28/22
Prothena Presents New Data for Alzheimer's and Parkinson's Disease Programs at AD/PD 2022GlobeNewsWire • 03/16/22
Prothena Corporation plc (PRTA) CEO Gene Kinney on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/18/22